HONG, HAO

Release date:2016-05-17  Release:


HONG, HAO

Professor of Pharmacology

School of Pharmacy

Phone: (025)86185227

Email: honghao@cpu.edu.cn

Research Summary

Professor HONG’s research focuses on the molecular targets of Alzheimer's disease and related diseases (such as depression and diabetes) using the methods of molecular biology and genetic.Recently, he found that cysteinyl leukotriene receptor 1 (CysLT1R) is involved in Aβ-inducedneurotoxicity and CysLT1R antagonist ameliorates Aβ-induced impairment of hippocampus plasticity and neuroinflammatory and apoptotic responses. He also found that abnormal transport of Aβacross the BBB is an important initiating factor in diabetes-associated cognitive decline, and rectifying the abnormalAβ transport across the BBB is an important strategy for prevention and treatment of diabetes-associated cognitive decline. His latest research shows that Hippocampal PPARδ regulates stress-induced depressive behaviors and neurogenesis arrest.

Current Grants

  1. The role of Cysteinyl Leukotriene Receptor 1 in Alzheimer’s Disease and Underlying Mechanisms

Principal Investigator: HONG HAO

Agency: NSF C, No. 81573413

Dates: 01/2016-12/2019

  1. The role of abnormal transport of β amyloid protein across the blood-brain barrier in cognitive dysfunction of diabetes mellitus

Principal Investigator: HONG HAO

Agency: NSF C, No. 81273497

Dates: 01/2013-12/2016


3. PPARδ as a potential antidepressant target and its underlying mechanism

Principal Investigator: HONG HAO

Agency: NSFJS, No. BK20131307

Dates: 06/ 2013-06/2016

Education

2005-2006Visiting Scholar in Pathological Physiology, Kinki  

University (Japan)

2001-2004Ph.D. in Pharmacology, China Pharmaceutical

University

1998-2001M.S. in Medicine, Anhui University of Traditional Chinese Medicine

1986-1989B.S. in Pharmacy, China Pharmaceutical          

University

Academic Experience

1981-1998 Senior/Junior Pharmacist, Anqing Hospital Affiliated with Anhui Medical University,

2004-present Professor/Associate Professor, School of Pharmacy, China Pharmaceutical University


Recent Publications

Chen F, Dong RR, Zhong KL, Ghosh A, Tang SS, Long Y, Hu M, Miao MX, Liao JM, Sun HB, Kong LY, Hong H*. Antidiabetic drugs restore abnormal transport of amyloid-β across the blood-brain barrier and memory impairment in db/db mice. Neuropharmacology, 2016; 101:123-36.


Wang H, Chen F, Zhong KL, Tang SS, Hu M, Long Y, Miao MX, Liao JM, Sun HB, Hong H*. PPARγ agonists regulate bidirectional transport of amyloid-β across the blood-brain barrier and hippocampus plasticity in db/db mice. Br J Pharmacol. 2016; 173(2):372-85.


Yu XB, Dong RR, Wang H, Lin JR, An YQ, Du Y, Tang SS, Hu M, Long Y, Sun HB, Kong LY, Hong H*. Knockdown of hippocampal cysteinyl leukotriene receptor 1 ameliorates depressive behavior and neuroinflammation induced by chronic mild stress in mice. Psychopharmacology, 2016; 233(9):1739-49.


An YQ, Zhang CT, Du Y, Zhang M, Tang SS, Hu M, Long Y, Sun HB, Hong H*. PPARδ agonist GW0742 ameliorates Aβ1-42-induced hippocampal neurotoxicity in mice. Metab Brain Dis, 2016; doi: 10.1007/s11011-016-9800-7.


Chen L, Hu L, Zhao J, Hong H, Feng F*, Qu W, Liu W*. Chotosan improves Aβ1-42-induced cognitive impairment and neuroinflammatory and apoptotic responses through the inhibition of TLR-4/NF-κB signaling in mice. J Ethnopharmacol, 2016; doi: 10.1016/j.jep.2016.03.038.


Ji MJ, Yu XB, Mei ZL, An YQ, Tang SS, Hu M, Long Y, Miao MX, Hu QH, Sun HB, Kong LY, Hong H*. Hippocampal PPARδ overexpression or activation represses stress-induced depressive behaviors and enhances neurogenesis. Int J Neuropsychopharmacol. 2015 Sep 10;19(1). pii: pyv083. doi: 10.1093/ijnp/pyv083.


Zhao YR, Qu W, Liu WY, Hong H*, Feng F*, Chen H, Xie N. YGS40, an active fraction of Yi-Gan San, reduces hydrogen peroxide-induced apoptosis in PC12 cells. 2015; 13(6):438-44.


Du GT, Hu M, Mei ZL, Wang C, Liu GJ, Hu M, Long Y, Miao MX, Chang Li J, Hong H*. Telmisartan treatment ameliorates memory deficits in streptozotocin-induced diabetic mice via attenuating cerebral amyloidosis. J Pharmacol Sci. 2014; 124(4):418-26.


Wang H, Mei Zl, Zhong KL, Hu M, Long Y, Miao MX, Li N, Yan TH, Hong H* Pretreatment with antiasthmatic drug ibudilast ameliorates Aβ 1-42-induced memory impairment and neurotoxicity in mice. Pharmacol Biochem Behav. 2014; 124:373-9


Lai J, Mei ZL, Wang H, Hu M, Long Y, Miao MX, Li N, Hong H*. Montelukast rescues primary neurons against Aβ1-42-induced toxicity through inhibiting CysLT1R-mediated NF-κB signaling. Neurochem Int. 2014; 75:26-31.


Lai J, Hu M, Wang H, Hu M, Long Y, Miao MX, Li JC, Wang XB, Kong LY, Hong H*. Montelukast targeting the cysteinyl leukotriene receptor 1 ameliorates Aβ1-42-induced memory impairment and neuroinflammatory and apoptotic responses in mice.Neuropharmacology.2014;79:707-714.


Tang SS, Hong H*, Chen L, Mei ZL, Ji MJ, Xiang GQ, Li N, Ji H. Involvement of cysteinyl leukotriene receptor 1 in Aβ1-42-induced neurotoxicity in vitro and in vivo. Neurobiol Aging. 2014; 35(3):590-599.


Tang SS, Ji MJ, Chen L, Hu M, Long Y, Li YQ, Miao MX, Li JC, Li N, Ji H, Chen XJ, Hong H*. Protective effect of pranlukast on Aβ1-42-induced cognitive deficits associated with downregulation of cysteinyl leukotriene receptor 1. Int J Neuropsychopharmacol. 2014;17(4):581-592.


Tang SS, Wang XY, Hong H*, Long Y, Li YQ, Xiang GQ, Jiang LY, Zhang HT, Liu LP, Ji H. Leukotriene D4 induces cognitive impairment through enhancement of CysLT1R-mediated amyloid-β generation in mice. Neuropharmacology. 2013; 65:182-92.


Wang XY, Tang SS, Hu M, Long Y, Li YQ, Liao MX, Ji H, Hong H*. Leukotriene D4 induces amyloid-β generation via CysLT(1)R-mediated NF-κB pathways in primary neurons. Neurochem Int. 2013; 62(3):340-7.


Liu LP, Yan TH, Jiang LY, Hu W, Hu M, Wang C, Zhang Q, Long Y, Wang JQ, Li YQ, Hu M, Hong H*. Pioglitazone ameliorates memory deficits in streptozotocin-induced diabetic mice by reducing brain β-amyloid through PPARγ activation. Acta Pharmacol Sin. 2013; 34(4):455-63.


Jiang LY, Tang SS, Wang XY, Liu LP, Long Y, Hu M, Liao MX, Ding QL, Hu W, Li JC, Hong H*. PPARγ agonist pioglitazone reverses memory impairment and biochemical changes in a mouse model of type 2 diabetes mellitus. CNS Neurosci Ther. 2012; 18(8):659-66.


Xiang GQ, Tang SS, Jiang LY, Hong H*, Li Q, Wang C, Wang XY, Zhang TT, Yin L. PPARγ agonist pioglitazone improves scopolamine-induced memory impairment in mice. J Pharm Pharmacol. 2012; 64(4):589-96.